Charles River Laboratories announces partnership with the Milner Therapeutics Institute and Consortium
Through this partnership, the academic institutions in the Consortium will have access to Charles River’s early discovery and drug development resources and services to accelerate their early-stage drug development processes.
University of Pittsburgh licenses novel microneedle patch to SkinJect
SkinJect Microneedle Patch to deliver drug to treat and immunize skin cancer patients.
Vonvendi, the first and only recombinant treatment for adults affected by von Willebrand disease, launches in the US
Vonvendi is a significant advancement for the treatment of adults with von Willebrand disease.
Microbiological environmental monitoring features in two national conferences supported by Cherwell Laboratories
Cherwell to offer expert insight in environmental monitoring and process validation to both NHS and industrial pharmaceutical manufacturers.
Biogen announces Bioverativ as name of new hemophilia-focused company
Bioverativ will focus on accelerating innovation for people living with hemophilia and other blood disorders.
Merck announces FDA filing acceptance of NDA for MK-1293, an investigational follow-on biologic insulin glargine
Marketing Authorization Application to the EMA currently under review.
Norgine and Valeant sign licensing agreement for NER1006 in US and Canada
Valeant obtains the rights to develop and commercialise NER1006 Powder for Oral Solution.
SMC ‘U-turn’ offers lifeline to Scottish skin cancer patients
Opdivo (nivolumab) now recommended to treat Scottish NHS patients with advanced skin cancer.
Dr Reddy’s completes acquisition of product portfolio from TEVA
The portfolio is a mix of six ANDAs pending approval, one approved ANDA and one ANDA with tentative approval, and comprises complex generic products across diverse dosage forms.